---

1. At a Glance

Imagine being born as Glenmark Life Sciences, only to be adopted by Nirma in 2024 and renamed Alivus Life Sciences. The company makes APIs for heart, diabetes, CNS and oncology, but still gets half its allowance from Glenmark Pharma (28% revenue share). Q1FY25 revenue: ₹602 Cr (+2.3% YoY), PAT: ₹122 Cr (+9%). Market cap: ₹11,509 Cr, P/E: 23x. Oh, and a casual ₹3 Cr customs fine sprinkled in—because desi pharma stories are incomplete without regulatory tadka.

---

2. Introduction

Alivus Life Sciences (formerly Glenmark Life Sciences) is like that engineering topper who moved into a rich household (Nirma) but still spends weekends with their old college gang (Glenmark Pharma).

The company makes active pharmaceutical ingredients (APIs) for chronic therapies—heart (Rosuvastatin, Olmesartan), diabetes (Sitagliptin), CNS (Zonisamide), oncology and more. Out of total Q3FY25 revenue, 95% came from APIs, with CDMO just 5%—proving that “services” is still the side hustle, not the main job.

The twist: In March 2024, Nirma Limited swooped in and bought 75% stake. Glenmark Pharma waved goodbye, and the rebranding exercise birthed “Alivus.” Sounds fancy, but the balance sheet still screams “API factory.”

So now the big investor question: Is Alivus going to be Divi’s Lab junior, or is it just Glenmark Life in a new kurta-pyjama?

---

3. Business Model – WTF Do They Even Do?

Alivus’ job is simple: cook molecules, file regulatory papers, and hope USFDA inspectors leave with a smile.

• API Business (95% revenue): High-value APIs for chronic diseases. Think cholesterol, BP, diabetes—the diseases your uncles discuss after every family wedding dinner. They’ve got 151 molecules in portfolio, 520 DMFs filed, and customers across the globe.
• CDMO Business (5% revenue): Basically “we’ll manufacture your complex chemistry if you pay well.” Small, but high-margin and stickier.
• Therapeutic Spread: CVS (44%), CNS (14%), Diabetes (5%), Pain Management (4%), Others (33%).
• Geography Split: 82% regulated markets (US, Europe, Japan), 18% emerging markets (aka “places where regulators ask fewer questions”).

Facilities? Five factories across Gujarat & Maharashtra with 1,424 KL capacity, heading to 2,650 KL by FY27 via Solapur expansion. Add 3 R&D centres, focus on HP APIs ($45 bn market), and you’ve got serious scale.

In short: They sell molecules your doctor prescribes but you never read the strip beyond expiry date.

---

4. Financials Overview

Metric	Latest Qtr (Q1FY25)	YoY Qtr (Q1FY24)	Prev Qtr (Q4FY25)	YoY %	QoQ %
Revenue	₹602 Cr	₹589 Cr	₹650 Cr	2.3%	-7.4%
EBITDA	₹172 Cr	₹159 Cr	₹198 Cr	8.2%	-13.1%
PAT	₹122 Cr	₹111 Cr	₹142 Cr	9.9%	-14.1%
EPS (₹)	9.9	9.1	11.6	8.8%	-14.7%

Commentary:
YoY growth is healthy, but QoQ numbers look like someone tripped carrying the chemistry flask. Margins (29%) remain stable, proving the company can sweat assets better than many mid-cap peers.

Annualised EPS = 9.9 × 4 = ₹39.6 → P/E ~ 23.6x (sane vs pharma peers).

Question: Is 23x P/E justified when half your cash still comes from your ex (Glenmark)?

---

5. Valuation Discussion – Fair Value Range

Method 1: P/E

Industry P/E: ~34.
Assign 20x–28x for Alivus.
EPS FY25E ~₹40.
Fair Value Range = ₹800–₹1,120.

Method 2: EV/EBITDA

EV = ₹11,495 Cr.
FY25E EBITDA (annualised from Q1) = 172 × 4 = ₹688 Cr.
Current EV/EBITDA ~16.7x.
Peer avg ~18–22x.
Fair EV range → ₹12,400–₹15,000 Cr → Equity Value ~₹12,300–₹14,900 Cr.
Per Share ≈ ₹1,000–₹1,200.

Method 3: DCF (basic)

Assume 10% revenue CAGR, margins stable, discount 11%, terminal growth 4%.
DCF throws ~₹900–₹1,050.

Final Fair Value Range: ₹800–₹1,200.
(Current CMP ₹937 is mid-range).

⚠️ Disclaimer: Educational purposes only, not investment advice.

---

6. What’s Cooking – News, Triggers, Drama

• Nirma Entry (2024): Company now has a stronger parent—financial muscle and consumer brand halo.
• Customs Fine (Aug 2025): ₹3 Cr fine, ₹10 L penalty, ₹6.5 L MEIS reversal. Classic “Indian pharma audit day.”